Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

81.13
-1.3200-1.60%
Post-market: 81.130.00000.00%17:32 EDT
Volume:1.69M
Turnover:137.43M
Market Cap:4.10B
PE:-19.30
High:84.55
Open:81.92
Low:80.35
Close:82.45
52wk High:88.02
52wk Low:13.37
Shares:50.54M
Float Shares:45.13M
Volume Ratio:1.20
T/O Rate:3.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2037
EPS(LYR):-4.2037
ROE:-38.38%
ROA:-24.58%
PB:8.31
PE(LYR):-19.30

Loading ...

Dianthus Therapeutics (DNTH) Gets a Buy from Evercore ISI

TIPRANKS
·
Mar 03

Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing

Simply Wall St.
·
Feb 07

Dianthus Therapeutics nimmt am Guggenheim Emerging Outlook: Biotech Summit teil

Reuters
·
Feb 05

U.S. RESEARCH ROUNDUP-Air Products, Chevron, UnitedHealth

Reuters
·
Feb 02

BRIEF-Dianthus Therapeutics May Issue Up To $600 Million In Securities

Reuters
·
Jan 29

Dianthus files $600M mixed securities shelf

TIPRANKS
·
Jan 29

Dianthus Therapeutics Inc - May Issue up to $600 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Dianthus Therapeutics (DNTH) and Biogen (BIIB)

TIPRANKS
·
Jan 28

Dianthus Therapeutics (DNTH) Is Up 15.5% After Positive Phase II MaGic gMG Data Revealed

Simply Wall St.
·
Jan 18

Assessing Whether Dianthus Therapeutics (DNTH) Valuation Still Holds After Recent Share Price Pullback

Simply Wall St.
·
Jan 11

Dianthus price target raised to $63 from $56 at Truist

TIPRANKS
·
Jan 08

Is Dianthus Therapeutics (DNTH) Using DNTH212’s Phase 1 Start To Redefine Its Autoimmune Strategy?

Simply Wall St.
·
Jan 07

Dianthus, Partner Say First Subject Dosed in Phase 1 Trial of Autoimmune Disease Treatment; Shares Up Pre-Bell

MT Newswires Live
·
Dec 23, 2025

Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus

Reuters
·
Dec 23, 2025

Leads Biolabs and Dianthus Therapeutics Announce Initiation of Phase 1 Trial of Lbl-047 (Dnth212) in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
Dec 23, 2025

Nanjing Leads Biolabs Co Ltd: Top-Line Results in Healthy Volunteers Anticipated in 2H'26

THOMSON REUTERS
·
Dec 23, 2025

Dianthus Therapeutics Licenses Global Rights to LBL-047 from Leads Biolabs

Reuters
·
Dec 23, 2025

Dianthus Therapeutics CFO & CBO Ryan Savitz Reports Disposal of Common Shares

Reuters
·
Dec 06, 2025

13D Filings -- Barrons.com

Dow Jones
·
Dec 06, 2025

Dianthus Therapeutics Joins Evercore Healthcare Conference

Reuters
·
Nov 24, 2025